Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Kestra Medical Technologies, Ltd. - Common Stock
Edit Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Maze Therapeutics, Inc. - Common Stock
(NQ:
MAZE
)
31.37
-1.06 (-3.27%)
Delayed Quote
Updated: 4:00 PM EST, Nov 20, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Maze Therapeutics, Inc. - Common Stock
Maze Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
November 09, 2026
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Maze Therapeutics to Participate in Upcoming Investor Conferences
November 03, 2026
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026
October 06, 2026
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Maze Therapeutics to Participate in Three Upcoming Investor Conferences
September 02, 2026
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Maze Therapeutics Announces Appointments to Its Board of Directors
August 13, 2026
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
August 11, 2026
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Maze Therapeutics to Participate in Two Upcoming Investor Conferences
May 27, 2026
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
May 12, 2026
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Maze Therapeutics Announces $150 Million Registered Offering
April 22, 2026
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
March 25, 2026
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease
March 25, 2026
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
February 25, 2026
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
February 04, 2026
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
January 05, 2026
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
November 06, 2025
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week
November 06, 2025
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Maze Therapeutics to Participate in Four Upcoming Investor Conferences
November 04, 2025
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors
October 06, 2025
Mr. Hoppenot, a seasoned biotech leader who has driven transformative therapies to market, joins Maze to fuel its evolution into a leading clinical-stage biotech
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement
September 11, 2025
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD)
September 11, 2025
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer
September 02, 2025
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights
August 12, 2025
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Maze Therapeutics to Participate in Two Upcoming Investor Conferences
July 10, 2025
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference
May 29, 2025
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones
May 14, 2025
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference
May 13, 2025
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights
March 31, 2025
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease
February 07, 2025
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1